Document 0117
 DOCN  M94A0117
 TI    Teniposide: overview of its therapeutic potential in adult cancers.
 DT    9412
 AU    Muggia FM; University of Southern California, Norris Cancer Center, Los;
       Angeles 90033.
 SO    Cancer Chemother Pharmacol. 1994;34 Suppl:S127-33. Unique Identifier :
       AIDSLINE MED/94349497
 AB    Teniposide was introduced into clinical trials prior to etoposide, but
       its role was not defined because interest shifted early on to etoposide.
       However, long-term encouraging results obtained in acute leukemia
       treated with teniposide have rekindled interest in this compound. In
       addition to pharmacokinetic differences, teniposide has greater CNS
       penetrance and is more lipophilic. Its greater potency is related to
       enhanced intracellular uptake. Although its antitumor spectrum of
       activity appears to be very similar to that of etoposide, a search for
       some differences might prove instructive.
 DE    Acquired Immunodeficiency Syndrome/COMPLICATIONS  Adult  Brain
       Neoplasms/DRUG THERAPY  Carcinoma, Non-Small-Cell Lung/DRUG THERAPY
       Carcinoma, Small Cell/DRUG THERAPY  Clinical Trials  Clinical Trials,
       Phase I  Comparative Study  Etoposide/TOXICITY/THERAPEUTIC USE  Female
       Genital Neoplasms, Female/DRUG THERAPY  Hodgkin's Disease/DRUG THERAPY
       Human  Leukemia/*DRUG THERAPY  Lung Neoplasms/DRUG THERAPY
       Lymphoma/*DRUG THERAPY  Lymphoma, Non-Hodgkin's/DRUG THERAPY
       Neoplasms/*DRUG THERAPY  Sarcoma, Kaposi's/DRUG THERAPY/ETIOLOGY
       Teniposide/*TOXICITY/*THERAPEUTIC USE  JOURNAL ARTICLE  REVIEW  REVIEW,
       TUTORIAL

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).